Page 554 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

a
Appendix Table C5.1. Proportion of patients on AS who went on to receive active treatments
AS Cohort Author, yr Median follow No. on AS No. % who
PMID up (range) received received
treatment active
treatment
Toronto Klotz, 2010 6.8 yr 450 135 30 (10 yr
19917860 (1-13 yr) actuarial 38%)

Krakowsky, 2010
20478589
Johns Hopkins Ross, 2010 2.9 yr 290 102 35
20439642 (0.48-12.2 yr)
U. of Miami Soloway, 2010 3.7 yr (mean) 230 32 14
20800964
Kagawa U. Kakehi, 2008 up to 4.5 yr 118 64 54 (3 yr
18272471 actuarial
51.1%)
b
McGill U. Al Otaibi, 2008 6.3 yr 92 had ≥1 rebiopsy 29 32
18484590 (1.7-14 yr)
PRIAS van den Bergh, 1.02 yr 500 82 16
2010 (0.6-1.5 yr)
19817747
Royal Marsden van As, 2009 2.4 yr (mean) 86 had ≥1 rebiopsy 39 45
19095345
c
UCSF Cooperberg, 2011 up to 4 yr 376 119 32
21115873
4 centers (Miami, UBC, Eggener, 2009 2.4 yr 262 43 16
Sloan-Kettering, Cleveland 19233410 (IQR 1.2, 4.3
Clinic) yr)
Dana Farber San Francisco, 2.4 yr 120 had ≥1 rebiopsy NR NR
2011
21167525
d
U. of Connecticut Ercole, 2008 4 yr 40 9 23
18707696 (1-14 yr)
e
Baylor or Sloan-Kettering Patel, 2004 3.7 yr 88 31 35
15017211
Sloan-Kettering Adamy, 2011 to 5 yr 238 NR NR
21167529
Cleveland Clinic Miocinovic, 2011 2.8 yr 116 had ≥1 rebiopsy 38 33
21256549 (IQR 1.7, 3.8
yr)
Canary PASS (Stanford, Newcomb, 2010 recruiting NR NR NR
UCSF, UBC, U of 19758683
Washington, U of Texas at
San Antonio)
ProtecT (multicenters in Metcalfe, 2009 Followup 408 (patients who NR NR
UK) 19603015 phase select AS actively:
observational cohort)
138 (randomized to
AS in the RCT)
AS = active surveillance; IQR = interquartile range; NR = not reported; U. = university; yr = year.

a Data from papers eligible for inclusion in this report.
b 6 had ADT alone
c 14 had ADT
d 2 had ADT
e 1 had ADT

C-195